Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients, ≥18- years of age at the time of Avelumab treatment initiation~2. Patients with locally advanced or metastatic urothelial cancer with any histology (histologically confirmed, unresectable locally advanced or metastatic urothelial carcinoma and/or documented Stage IV disease (per American Joint Committee on Cancer/International Union for Cancer Control TNM system1 19-21) at the start of first-line chemotherapy)~3. Patients who have completed first-line platinum-based chemotherapy with no evidence of disease progression according to medical chart (ie, with a SD, PRor complete response \[CR\]).~4. Patients who are receiving or have received at least one dose of Avelumab as the firstl ine maintenance therapy according to label indication~5. Patients with ongoing treatment with Avelumab who provided written informed consent allowing the data collection. For decease patients and those who are lost to follow-up, an approved ICF waiver is allowed.~Exclusion Criteria:~* Patients who have participated in any interventional clinical trial of a drug or device within 28- days prior to the start of Avelumab maintenance therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with Advanced or Metastatic Urothelial Cancer (Type: None): Patients with Advanced or Metastatic Urothelial Cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).